BR0307058A - N-óxidos de derivados de n-fenil-2-pirimidina-amina - Google Patents

N-óxidos de derivados de n-fenil-2-pirimidina-amina

Info

Publication number
BR0307058A
BR0307058A BR0307058-1A BR0307058A BR0307058A BR 0307058 A BR0307058 A BR 0307058A BR 0307058 A BR0307058 A BR 0307058A BR 0307058 A BR0307058 A BR 0307058A
Authority
BR
Brazil
Prior art keywords
oxides
phenyl
amine derivatives
pyrimidine amine
pyrimidine
Prior art date
Application number
BR0307058-1A
Other languages
English (en)
Inventor
Klaus Olaf B Rnsen
Peter End
Gerhard Gross
Ulrike Pfaar
Paul William Manley
Jurg Zimmermann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9929594&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0307058(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0307058A publication Critical patent/BR0307058A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

"N-óXIDOS DE DERIVADOS DE N-FENIL-2-PIRIMIDINA-AMINA". A presente invenção refere-se a derivados de N-fenil-2-pirimidina-amina em que pelo menos um átomo de nitrogênio apresenta um átomo de oxigênio para formar os correspondentes N-óxidos, a processos para preparação dos mesmos, a composições farmacêuticas compreendendo os compostos e ao uso dos mesmos na preparação de composições farmacêuticas para tratamento terapêutico de animais de sangue quente, incluindo seres humanos.
BR0307058-1A 2002-01-23 2003-01-22 N-óxidos de derivados de n-fenil-2-pirimidina-amina BR0307058A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0201508.9A GB0201508D0 (en) 2002-01-23 2002-01-23 Organic compounds
PCT/EP2003/000613 WO2003062220A1 (en) 2002-01-23 2003-01-22 N-oxyde of n-phenyl-2-pyrimidine-amine derivatives

Publications (1)

Publication Number Publication Date
BR0307058A true BR0307058A (pt) 2004-12-28

Family

ID=9929594

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307058-1A BR0307058A (pt) 2002-01-23 2003-01-22 N-óxidos de derivados de n-fenil-2-pirimidina-amina

Country Status (15)

Country Link
US (5) US7557105B2 (pt)
EP (3) EP1783126A3 (pt)
JP (2) JP4213595B2 (pt)
KR (2) KR20070058019A (pt)
CN (2) CN101468984A (pt)
AT (1) ATE380807T1 (pt)
BR (1) BR0307058A (pt)
CA (1) CA2474104C (pt)
DE (1) DE60318013T2 (pt)
ES (2) ES2503734T3 (pt)
GB (1) GB0201508D0 (pt)
IL (2) IL162979A (pt)
MX (1) MXPA04007130A (pt)
PT (2) PT1470120E (pt)
WO (1) WO2003062220A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE399766T1 (de) * 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
MXPA05013349A (es) * 2003-06-13 2006-03-09 Novartis Ag Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
KR20070053205A (ko) 2004-09-17 2007-05-23 에자이 알앤드디 매니지먼트 가부시키가이샤 의약 조성물
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
AU2006309551B2 (en) * 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
CA2634047C (en) * 2005-12-21 2016-04-12 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
EP2036557B1 (en) * 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
MX2009002336A (es) * 2006-09-01 2009-03-20 Teva Pharma Composiciones de imatinib.
US20080103305A1 (en) * 2006-10-26 2008-05-01 Macdonald Peter Process for the preparation of imatinib
EP2009008A1 (en) * 2006-10-26 2008-12-31 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
CN101225085B (zh) * 2007-01-17 2011-09-21 天津天士力集团有限公司 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
CN101245061B (zh) * 2007-02-13 2012-09-19 天津天士力集团有限公司 N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶胺类一氧化氮供体型衍生物，制备方法及其用途
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
EP2152079A4 (en) * 2007-06-04 2011-03-09 Avila Therapeutics Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
US9062023B2 (en) 2007-06-07 2015-06-23 Intra-Cellular Therapies, Inc. Heterocycle compounds and uses thereof
JP5710251B2 (ja) 2007-06-07 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規ヘテロ環化合物およびその使用
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions
AU2008325608B2 (en) * 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EP2248804A4 (en) * 2008-01-29 2014-09-10 Eisai R&D Man Co Ltd COMBINED USE OF AN ANGIOGENESIS INHIBITOR AND A TAXANE
US20110027126A1 (en) * 2008-03-26 2011-02-03 Merck Patent Gesellschaft Mit Beschrankter Haftung Method of long term storage of substrate-coupled beads
CN101417995B (zh) * 2008-11-21 2012-06-06 陈依军 苯氧基嘧啶衍生物及其制备方法和用途
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
RU2580609C2 (ru) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
EP2937337A4 (en) 2012-12-21 2016-06-22 Eisai R&D Man Co Ltd AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103588754B (zh) * 2013-11-04 2015-05-27 遵义医学院 伊马替尼的制备方法
TWI721954B (zh) 2014-08-28 2021-03-21 日商衛材R&D企管股份有限公司 高純度喹啉衍生物及其生產方法
RU2017128583A (ru) 2015-02-25 2019-03-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ ослабления горечи хинолинового производного
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
CN107573322A (zh) * 2017-09-06 2018-01-12 南京优科生物医药研究有限公司 伊马替尼双氮氧化物、其制备方法和用途
CN109761970B (zh) * 2019-01-26 2020-06-09 中国药科大学 一种蛋白靶向降解嵌合分子、制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607041A (en) * 1983-04-27 1986-08-19 Fisons Plc Antihypertensive 2-phenyl Hantzsch dihydropyridines
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (pt) * 1992-04-03 1994-06-21 Ciba Geigy Ag
DE4444288A1 (de) * 1994-12-13 1996-06-20 Rainer Dr Med Etzel Verwendung von Weihrauch zur Behandlung der Alzheimer-Krankheit
MX9706449A (es) * 1995-02-28 1997-11-29 Hoechst Marion Roussel Inc Composicion farmaceutica para compuestos de piperidinalcanol.
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments

Also Published As

Publication number Publication date
PT1470120E (pt) 2008-03-03
EP1783126A3 (en) 2008-11-26
CN100467461C (zh) 2009-03-11
JP4213595B2 (ja) 2009-01-21
ATE380807T1 (de) 2007-12-15
US7557105B2 (en) 2009-07-07
EP2194049B1 (en) 2014-08-13
IL162979A (en) 2010-12-30
JP2009051837A (ja) 2009-03-12
IL208399A0 (en) 2010-12-30
CN1646519A (zh) 2005-07-27
US20050209452A1 (en) 2005-09-22
US20090239879A1 (en) 2009-09-24
IL208399A (en) 2013-02-28
EP1783126A2 (en) 2007-05-09
KR20040081467A (ko) 2004-09-21
DE60318013T2 (de) 2008-11-13
JP2005519908A (ja) 2005-07-07
WO2003062220A1 (en) 2003-07-31
EP1470120A1 (en) 2004-10-27
MXPA04007130A (es) 2004-10-29
ES2503734T3 (es) 2014-10-07
US20110294820A1 (en) 2011-12-01
ES2294293T3 (es) 2008-04-01
DE60318013D1 (de) 2008-01-24
CA2474104C (en) 2012-04-17
JP5027076B2 (ja) 2012-09-19
PT2194049E (pt) 2014-11-10
US20100222362A1 (en) 2010-09-02
US20140323494A1 (en) 2014-10-30
CN101468984A (zh) 2009-07-01
CA2474104A1 (en) 2003-07-31
EP2194049A1 (en) 2010-06-09
EP1470120B1 (en) 2007-12-12
GB0201508D0 (en) 2002-03-13
KR20070058019A (ko) 2007-06-07
KR100778163B1 (ko) 2007-11-28

Similar Documents

Publication Publication Date Title
BR0307058A (pt) N-óxidos de derivados de n-fenil-2-pirimidina-amina
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
BR0308452A (pt) composições farmacêuticas e métodos de preparação de composição farmacêutica
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
CY1119309T1 (el) Συνδυασμενη χρηση toy (+)-1,4-διϋδρο-7-[(3s,4s)-3-meθoξy-4-(μεθυλαμινο)-1-πυρρολιδινυλ]-4-οξο-1(2-θειαζολυλ)-1,8-ναφθυριδιν-3-καρβοξυλικου οξεος και της κυταραβινης (ara-c) για την αγωγη της λευχαιμιας
ATE454378T1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
SE0301700D0 (sv) Novel compounds
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
WO2005111002A3 (de) Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen
TW200510297A (en) Substituted n-aryl heterocycles, process for their preparation and their use as medicaments
ECSP066311A (es) Derivados de la piperazina y su uso como agentes terapéuticos
IL163090A (en) Nicotinamide derivates, pharmaceutical compositions comprising them and their use for manufacture of medicaments useful as p38 inhibitors
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
ATE358485T1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
ATE233754T1 (de) Diphenyl-piperidin derivate
SE0300457D0 (sv) Novel compounds
NO20070878L (no) Dimere piperidinderivater
AU2003245989A8 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
ATE325809T1 (de) Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl- amino-5-phenyl-pentansäure
PL1612210T3 (pl) Nowe analogi nitrobenzylotioinozyny
DK1708693T3 (da) Farmaceutiske sammensætninger indeholdende platinkomplekser med sekundære xanthater og terapeutiske anvendelser deraf
ATE327240T1 (de) 2ß OXO-VORUSCHARIN UND DERIVATEN

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]